Altimmune Reports $31.6 Million Q3 Net Loss, $480 Million in Cash

Altimmune reported a third-quarter 2026 net loss of $31.6 million, or $0.15 per share, compared with a $19.0 million loss a year earlier. Research and development expenses rose to $27.0 million as the company advanced its clinical programs. Cash, cash equivalents and investments totaled $480 millio…